Introduction

Europe was certified polio-free in 2002 but the threat of reintroduction of wild-type poliovirus into the EU/EEA area remains as long as polio has not been eradicated. The detection of wild-type poliovirus transmission in Israel, and the outbreaks of paralytic poliomyelitis in Syria and parts of the Horn of Africa in 2013, increased the risk of importation to the EU/EEA. There are concerns about the quality of surveillance for acute flaccid paralysis (AFP) in the EU/EEA, and about the capacity to detect and respond to poliovirus transmission in a timely manner [1].

This document discusses options for EU/EEA Member States to enhance their polio surveillance, mitigate risks and respond to outbreaks in the EU/EEA. It is based on three ECDC risk assessments that were published in 2013, an ECDC-convened expert consultation meeting, literature review, and discussions with experts in polio [2-5]. The focus is on options for strengthening polio preparedness in EU/EEA Member States and the aim is to support decision-making processes. The following areas are covered:

- surveillance of poliovirus and acute flaccid paralysis,
- risk mitigation,
- outbreak response and choice of vaccine, and
- comparison of the use of oral poliovirus vaccine and inactivated polio vaccine as an outbreak response.

Surveillance

- Member States should assess the quality their poliovirus surveillance and determine whether it needs to be strengthened. The Regional Polio Eradication Certification Commission for Europe (RCC) regularly assesses the quality of national polio surveillance based on country reports, and the RCC’s findings and recommendations should form the basis for action [1].

- Member States who primarily rely on AFP surveillance should determine whether the surveillance index fulfils the WHO minimum standard of ≥0.8, as calculated in WHO EpiData [6]. Countries with an index below 0.8 should identify the reasons why the AFP surveillance system is not performing well.
  - If the system is close to meeting the AFP performance indicator of 0.8, countries are encouraged to make the necessary changes or investment to reach the 0.8 standard (e.g. by improving the clinical component).
  - If improvements to AFP surveillance are not considered feasible, then strengthening the environmental and enterovirus surveillance should be considered as supplements.

- Member States are not recommended to screen asymptomatic people for poliovirus infection, but if they nevertheless consider initiating such screening, they are encouraged to first consult with ECDC or WHO and to ensure that there are resources available to address any positive findings.
Member States should take an active role to ensure that the healthcare workforce can appropriately identify and test possible cases of poliomyelitis.

Risk mitigation

- Given that the consequences of poliovirus transmission will be most severe in unvaccinated individuals and that poliovirus transmission will be most effective in populations with low vaccination uptake, Member States should review their immunisation coverage and close immunity gaps in geographic areas and population groups with inadequate vaccination coverage.
- Member States should ensure that the vaccination status of refugees and migrants from polio-affected countries [7] is assessed at the time of entry into the EU/EEA area, and that people missing polio or other vaccines are offered vaccinations that are appropriate for their age and previous vaccination status (if known) as per the host country schedule.
- All refugees and migrants who are vaccinated in or before entry to the EU/EEA should have their vaccinations recorded on a personal vaccination card. If they do not have one, such a card should be provided to them, either the generic WHO ‘Yellow Card’ or the vaccination card used in the EU/EEA country where the individual is vaccinated. The vaccine provider should record vaccinations given to refugees and migrants in the national records.
- Member States should encourage their residents to be fully vaccinated against polio before traveling to polio-infected regions. Adults should have received at least one booster dose after the primary childhood series.

Vaccines and outbreak response

- A single case of poliovirus infection in a polio-free region is considered an outbreak and must be responded to quickly.
- Member States should test, and when necessary update, their national preparedness plans with support from ECDC and WHO.
- IPV has a role in polio outbreak control under certain circumstances, as demonstrated by the successful response to small outbreaks in Australia [8], the United States [9] and Sweden [10] (see Table, below, for overview of IPV and OPV). Circumstances under which vaccination with IPV could constitute an adequate vaccination response include those when contact tracing and environmental surveillance produce no evidence of widespread or sustained wild-type poliovirus (WPV) transmission. A typical scenario would be a single case of WPV infection in a person who has come directly from an area with polio circulation, or when transmission is limited to within a household that is part of a highly vaccinated community.

Outbreak response vaccination with IPV is justified in the EU/EEA under the circumstances described above because the risk of WPV transmission within a given population is determined by the vaccination coverage and the standard of water and sanitation. In areas with good sanitation, such as the EU/EEA, oral–oral transmission of poliovirus may be more important than faecal–oral transmission. IPV induces similar immunity in the oropharynx as OPV and both OPV and IPV prevent paralytic disease and oral transmission. Although IPV induces weaker gut mucosal immunity than OPV, it does reduce the duration and concentration of faecal polio excretion, and this is likely to impact on transmission [11] [12]. Scientific evidence suggests that, in settings with high hygiene standards, IPV is able to prevent continued transmission from an outbreak. This was demonstrated during the 1992 polio outbreak in the Netherlands where it was shown that people vaccinated with IPV did not contribute to the circulation of the WPV (healthy IPV-vaccinated individuals were not found to excrete poliovirus) [13-15].

- Member States would be responsible for identifying and obtaining the necessary IPV to control an outbreak of WPV.
- While the use of IPV for outbreak response means that the population will not be at risk of developing vaccine-associated paralytic poliomyelitis (VAPP) or from circulating vaccine-derived poliovirus, it is possible for non-paralytic WPV transmission to be sustained in a highly vaccinated population, as recently demonstrated in Israel. Thus, careful post-outbreak monitoring is necessary to ensure that there is no silent transmission of WPV occurring.
- When there is evidence of sustained transmission (for example, multiple environmental sites positive for poliovirus; persistent environmental samples in a single site, even in the absence of disease; or multiple unrelated cases of disease) or when there is evidence of WPV transmission in a vaccine-naïve population, then monovalent or bivalent OPV is the vaccine of choice for controlling the outbreak and preventing paralytic disease. If OPV is not immediately available, IPV may be used to reduce the risk of paralytic disease. High coverage with doses of OPV may be needed to break the chain of transmission.
- When OPV is used to respond to an outbreak, type-specific monovalent OPV (mOPV) should be the first choice.
for outbreak response. The next best choice is bivalent OPV (bOPV), followed by trivalent OPV (tOPV) if no other OPV is available or cannot be used due to regulatory constraints.

- OPV is not in routine use in the EU/EEA, with the exception of Poland. It is only licensed in those EU/EEA countries where it is produced for export (Belgium, France and Italy), and in Bulgaria and Poland where trivalent OPV is licensed. Lack of marketing authorisation in many countries limits accessibility to OPV unless regulatory provisions are made for emergency use. Countries need to take early action regarding licensing to ensure availability of OPV before they are faced with poliovirus introduction, and possible public resistance to an unauthorised product used under emergency provisions. The European Medicines Agency has a pivotal role in facilitating licensing options for OPV for those Member States currently with no licensed OPV product.

- Should an outbreak occur, all EU/EEA Member States will have access to the global OPV stockpile managed by WHO and UNICEF for emergency use; OPV stockpiling for emergency use in the EU/EEA is not encouraged because of limited supply and shelf-life.

- If OPV is used, communication messages should clarify that there is virtually no risk of VAPP from OPV use in persons previously vaccinated with IPV. Campaign messaging should be that OPV use is necessary to provide mucosal immunity, reduce virus shedding, and stop transmission.

- If OPV is used for outbreak control, individuals with known allergy to vaccine components and those with immunosuppression, and their household contacts, should receive IPV and not OPV.

### Table. Advantages and disadvantages of OPV versus IPV for outbreak response in EU/EEA

<table>
<thead>
<tr>
<th>Attribute</th>
<th>OPV</th>
<th>IPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine-associated paralytic poliomyelitis</td>
<td>Rare</td>
<td>None</td>
</tr>
<tr>
<td>Emergence of circulating vaccine-derived poliovirus</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Other serious adverse events</td>
<td>None known</td>
<td>Possible provocation paralysis in patient incubating polio at time of injection</td>
</tr>
<tr>
<td>Use in immunocompromised/family</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Systemic immunity</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Mucosal immunity</td>
<td>High</td>
<td>Lower in the intestinal tract</td>
</tr>
<tr>
<td>Secondary transmission of vaccine virus</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Prevent paralytic disease</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Prevent transmission</td>
<td>Yes</td>
<td>Possibly reduced</td>
</tr>
<tr>
<td>Public acceptance</td>
<td>Possibly reduced</td>
<td>Potentially higher</td>
</tr>
<tr>
<td>Regulatory approval in EU/EEA</td>
<td>Approved in a few Member States</td>
<td>Approved in all Member States</td>
</tr>
<tr>
<td>Stockpile availability</td>
<td>Yes (UNICEF)</td>
<td>Some Member States have stockpiles</td>
</tr>
<tr>
<td>Current cost</td>
<td>Low</td>
<td>Higher</td>
</tr>
<tr>
<td>Use in outbreaks</td>
<td>All outbreaks</td>
<td>Outbreaks with limited cases/transmission</td>
</tr>
</tbody>
</table>

IPV: inactivated poliovirus vaccine, OPV: oral poliovirus vaccine.
References


